Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis.

Purpose: Selinexor is a first-in-class, oral selective-inhibitor-of-nuclear-export, granted accelerated approval by FDA (2019) for relapsed and refractory multiple myeloma (RRMM). We sought to quantitatively summarize the selinexor efficacy and safety in RRMM.

Methods: We searched PubMed, EMBASE, CENTRAL, clinicaltrial.

Risen Alive: The Lazarus Phenomenon.

The Lazarus phenomenon described as delayed return of spontaneous circulation (ROSC) after cessation of CPR is rare, though underreported. We present the case of a 25-year-old woman who visited our hospital for persistent vomiting and weight loss for the last six months following bariatric surgery. On the 16 day of admission, the patient experienced cardiac arrest (code blue).